Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
about
Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.Problem or solution: The strange story of glucagon.Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
P2860
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@nl
type
label
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.
@en
P2093
Danielle Armas
David Klein
Diane J Plotkin
Douglas Logan
Eric G Vajda
J D Pipkin
Keith B Marschke
Kenneth Lasseter
P2860
P356
10.1111/DOM.12752
P577
2016-08-08T00:00:00Z